Calcitonin

Overview

Calcitonin is a 32-amino-acid peptide hormone secreted by the parafollicular cells (C-cells) of the thyroid gland in response to elevated serum calcium levels. First identified in 1962 by Harold Copp, calcitonin plays a physiological role in calcium homeostasis by inhibiting osteoclast activity and thereby reducing bone resorption and lowering blood calcium concentrations. It functions as a counterregulatory hormone to parathyroid hormone (PTH), which stimulates bone resorption and raises serum calcium.

The therapeutic use of calcitonin centers on salmon calcitonin (sCT), which is approximately 40-50 times more potent than human calcitonin due to higher receptor binding affinity and greater resistance to metabolic degradation. Salmon calcitonin has been approved for clinical use in several formulations:

• Miacalcin — injectable and nasal spray formulations for osteoporosis
• Fortical — nasal spray formulation
• Various generic preparations available worldwide

Calcitonin was among the first peptide hormones used therapeutically for osteoporosis and remains relevant in clinical practice, although its role has diminished with the introduction of more potent antiresorptive agents (bisphosphonates, denosumab) and anabolic agents such as teriparatide. Calcitonin retains a niche role in acute hypercalcemia management, Paget disease of bone, and short-term pain relief following osteoporotic vertebral fractures.

The calcitonin gene also gives rise to calcitonin gene-related peptide (CGRP) through alternative RNA splicing — a neuropeptide with distinct functions in pain signaling and vasodilation that has become a major target in migraine therapeutics.

Structure and Sequence

Human calcitonin sequence: Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH₂

Salmon calcitonin sequence: Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH₂

• Molecular weight: Approximately 3,418 g/mol (human); 3,432 g/mol (salmon)
• Key structural features:
  • Disulfide bridge: Cys1-Cys7 disulfide bond forms an N-terminal ring structure essential for receptor binding and biological activity
  • C-terminal amidation: Prolineamide at position 32 is required for full biological activity
  • Amphipathic helix: Central region (residues 8-22) forms an alpha-helix that interacts with the receptor extracellular domain
  • Species differences: Salmon calcitonin shares only approximately 50% sequence homology with human calcitonin, yet its structural differences confer enhanced receptor affinity and metabolic stability

The greater potency of salmon calcitonin is attributed to its more stable alpha-helical structure in solution and its resistance to enzymatic degradation, resulting in higher effective receptor occupancy at equivalent doses.

Mechanism of Action

Calcitonin Receptor Signaling

Calcitonin acts primarily through the calcitonin receptor (CTR), a class B G-protein coupled receptor highly expressed on osteoclasts:

Bone Effects:

• Osteoclast inhibition: Binding to CTR on mature osteoclasts rapidly induces cell quiescence, characterized by loss of the ruffled border and cessation of bone resorption. This effect occurs within minutes and is mediated through cAMP-dependent and phospholipase C-dependent signaling cascades.
• Osteoclast retraction: Calcitonin causes cytoskeletal reorganization in osteoclasts, disrupting the sealing zone required for resorption lacuna formation
• Receptor downregulation: Chronic calcitonin exposure leads to CTR internalization and downregulation, which causes the "escape phenomenon" — diminished therapeutic response with prolonged use

Renal Effects:

• Increases urinary excretion of calcium and phosphate by inhibiting tubular reabsorption
• Reduces sodium and chloride reabsorption in the proximal tubule

Central Nervous System:

• Analgesic effects that appear independent of its calcium-regulatory actions, possibly mediated through central serotonergic and beta-endorphin pathways
• CTR expression in hypothalamic regions involved in pain modulation and appetite regulation

Calcitonin Receptor Complexity

The calcitonin receptor forms heteromeric complexes with receptor activity-modifying proteins (RAMPs), creating receptors with different ligand specificities:

• CTR alone — calcitonin receptor (responds to calcitonin)
• CTR + RAMP1 — amylin receptor (AMY1)
• CTR + RAMP2 — amylin receptor (AMY2)
• CTR + RAMP3 — amylin receptor (AMY3)

This receptor promiscuity means that calcitonin at pharmacological doses can activate amylin receptors, potentially contributing to effects on appetite and gastric emptying that overlap with those of pramlintide.

Research Summary

Pharmacokinetics

• Half-life: Approximately 10-15 minutes (injectable); effective duration of action is longer (6-8 hours for calcium-lowering)
• Bioavailability: Nearly 100% (injectable); approximately 3% (nasal spray); oral bioavailability is very low without absorption enhancers
• Time to peak: 15-25 minutes (injectable); 30-40 minutes (nasal)
• Metabolism: Rapid degradation by peptidases in plasma, kidney, and peripheral tissues; kidney is the primary site of clearance
• Tachyphylaxis: A clinically significant phenomenon — receptor desensitization leads to diminished response after 48-72 hours of continuous administration (relevant for hypercalcemia management) and with long-term use for osteoporosis
• Intranasal formulation specifics: Absorption from nasal mucosa is variable; alternating nostrils is recommended to reduce local irritation

Common Discussion Topics

Escape phenomenon and tachyphylaxis: The most distinctive pharmacological feature of calcitonin therapy is the development of resistance with prolonged use. Continuous CTR activation leads to receptor internalization and reduced surface expression, diminishing the antiresorptive effect. This limits calcitonin's utility as a long-term osteoporosis therapy and necessitates intermittent dosing strategies or combination approaches.

Analgesic properties in vertebral fractures: Calcitonin's pain-relieving effects following acute vertebral compression fractures represent its most distinctive clinical niche. The analgesic mechanism appears to involve central modulation of pain pathways rather than simply reduced bone resorption, and the effect is observed more rapidly than would be expected from skeletal mechanisms alone.

Cancer safety signal: A 2012 European Medicines Agency (EMA) review identified a small but statistically significant increase in cancer incidence with long-term calcitonin use. While the FDA did not withdraw approval, recommendations shifted toward limiting treatment duration to 6 months for osteoporosis. The mechanism of any potential cancer association remains unclear.

Relationship to CGRP: The calcitonin and CGRP genes arise from alternative splicing of the CALC1 gene. While calcitonin is primarily produced in thyroid C-cells, CGRP predominates in sensory neurons. This shared genetic origin connects calcium metabolism with pain physiology.

Diminished clinical role: With the availability of bisphosphonates, denosumab, and anabolic agents like teriparatide, calcitonin has been relegated from first-line osteoporosis therapy to a specialized role in acute fracture pain and short-term hypercalcemia management.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines for salmon calcitonin. Always consult a qualified healthcare professional.

Important considerations: Treatment duration for osteoporosis is generally limited to 6 months due to the cancer safety signal identified by the EMA. Tachyphylaxis (escape phenomenon) may diminish response with prolonged continuous use. Ensure adequate calcium and vitamin D intake during treatment.

Related Compounds

• Teriparatide — PTH(1-34) fragment with anabolic bone-building effects, contrasting with calcitonin's antiresorptive mechanism
• CGRP — alternative splice product of the calcitonin gene with distinct vasodilatory and pain-related functions
• Pramlintide — amylin analog that signals through calcitonin receptor-RAMP complexes